Effect of Oral Digoxin in High-Risk Heart Failure Patients: A Pre-Specified Subgroup Analysis of the DIG Trial
Year: 2013
Type: article
Abstract: AIMS: In the Digitalis Investigation Group (DIG) trial, digoxin reduced mortality or hospitalization due to heart failure (HF) in several pre-specified high-risk subgroups of HF patients, but data on protocol-specified 2-year outcomes were not presented. In the current study, we examined the effect of digoxin on HF death or HF hospitalization and all-cause death or all-cause hospitalization in high-risk subgroups during the protocol-specified 2 years of post-randomization follow-up. METHODS AND RESULTS: In the DIG trial, 6800 ambulatory patients with chronic HF, normal sinus rhythm, and LVEF ≤45% (mean age 64 years, 26% women, 17% non-whites) were randomized to receive digoxin or placebo. The three high-risk groups were defined as NYHA class III-IV symptoms (n = 2223), LVEF <25% (n = 2256), and cardiothoracic ratio (CTR) >55% (n = 2345). In all three high-risk subgroups, compared with patients in the placebo group, those in the digoxin group had a significant reduction in the risk of the 2-year composite endpoint of HF mortality or HF hospitalization: NYHA III-IV [hazard ratio (HR) 0.65; 95% confidence interval (CI) 0.57-0.75; P < 0.001], LVEF <25% (HR 0.61; 95% CI 0.53-0.71; P < 0.001), and CTR >55% (HR 0.65; 95% CI 0.57-0.75; P < 0.001). Digoxin-associated HRs (95% CI) for 2-year all-cause mortality or all-cause hospitalization for subgroups with NYHA III-IV, LVEF <25%, and CTR >55% were 0.88 (0.80-0.97; P = 0.012), 0.84 (0.76-0.93; P = 0.001), and 0.85 (0.77-0.94; P = 0.002), respectively. CONCLUSIONS: Digoxin improves outcomes in chronic HF patients with NYHA class III-IV, LVEF <25%, or CTR >55%, and should be considered in these patients.
Institutions: Northwestern University, University of Alabama at Birmingham, University General Hospital Attikon, Istituti di Ricovero e Cura a Carattere Scientifico, IRCCS San Raffaele Roma, University Medical Center Groningen, Hull York Medical School, University of Brescia, University of North Carolina at Chapel Hill, University of Glasgow, Birmingham VA Medical Center
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: digoxin, heart failure, Digitalis Investigation Group trial, high-risk subgroups, NYHA class III-IV, reduced ejection fraction, cardiothoracic ratio, heart failure mortality, heart failure hospitalization, all-cause mortality, all-cause hospitalization, subgroup analysis, chronic heart failure, sinus rhythm
Open Access status: green
OpenAlex ID: W2126847055
